173 related articles for article (PubMed ID: 34590436)
21. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
Falchook AD; Basak R; Mohiuddin JJ; Chen RC
Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
[TBL] [Abstract][Full Text] [Related]
22. Androgen deprivation therapy for prostate cancer and the risk of thyroid diseases.
Liu JM; Chen YT; Wu CT; Hsu WL; Hsu RJ
Prostate; 2022 May; 82(7):809-815. PubMed ID: 35226371
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer.
Bekelman JE; Mitra N; Handorf EA; Uzzo RG; Hahn SA; Polsky D; Armstrong K
J Clin Oncol; 2015 Mar; 33(7):716-22. PubMed ID: 25559808
[TBL] [Abstract][Full Text] [Related]
24. Androgen Deprivation Therapy and the Risk of Dementia after Treatment for Prostate Cancer.
Lonergan PE; Washington SL; Cowan JE; Zhao S; Broering JM; Cooperberg MR; Carroll PR
J Urol; 2022 Apr; 207(4):832-840. PubMed ID: 34854749
[TBL] [Abstract][Full Text] [Related]
25. Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
Eur Urol; 2014 Mar; 65(3):620-7. PubMed ID: 23245686
[TBL] [Abstract][Full Text] [Related]
26. Androgen deprivation therapy and the risk of iron-deficiency anaemia among patients with prostate cancer: a population-based cohort study.
Wu FJ; Li IH; Chien WC; Shih JH; Lin YC; Chuang CM; Cheng YD; Kao LT
BMJ Open; 2020 Mar; 10(3):e034202. PubMed ID: 32213519
[TBL] [Abstract][Full Text] [Related]
27. Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: A population-based study.
Lee YHA; Hui JMH; Chan JSK; Liu K; Dee EC; Ng K; Tang P; Tse G; Ng CF
Prostate; 2023 Jan; 83(1):119-127. PubMed ID: 36178848
[TBL] [Abstract][Full Text] [Related]
28. Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer.
Ong WL; Foroudi F; Evans S; Millar J
BJU Int; 2017 Nov; 120 Suppl 3():35-42. PubMed ID: 28749017
[TBL] [Abstract][Full Text] [Related]
29. Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders.
Liu JM; Liu YP; Chuang HC; Wu CT; Su YL; Hsu RJ
PLoS One; 2020; 15(2):e0229263. PubMed ID: 32074125
[TBL] [Abstract][Full Text] [Related]
30. Associations between statin use and progression in men with prostate cancer treated with primary androgen deprivation therapy.
Mikkelsen MK; Thomsen FB; Berg KD; Jarden M; Larsen SB; Hansen RB; Brasso K
Scand J Urol; 2017 Dec; 51(6):464-469. PubMed ID: 28831860
[TBL] [Abstract][Full Text] [Related]
31. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
[TBL] [Abstract][Full Text] [Related]
32. No increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men.
Wang LH; Liu CK; Chen CH; Kao LT; Lin HC; Huang CY
Andrology; 2016 Jan; 4(1):128-32. PubMed ID: 26711703
[TBL] [Abstract][Full Text] [Related]
33. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
[TBL] [Abstract][Full Text] [Related]
34. Periprostatic Fat Thickness on MRI is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Chinese Patients With Newly Diagnosed Prostate Cancer Treated With Androgen Deprivation Therapy.
Huang H; Chen S; Li W; Bai P; Wu X; Xing J
Clin Genitourin Cancer; 2019 Oct; 17(5):e1036-e1047. PubMed ID: 31281063
[TBL] [Abstract][Full Text] [Related]
35. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
Fu AZ; Tsai HT; Haque R; Yood MU; Cassidy-Bushrow AE; Van Den Eeden SK; Keating NL; Smith MR; Zhou Y; Aaronson DS; Potosky AL
J Urol; 2017 Jun; 197(6):1448-1454. PubMed ID: 28007467
[TBL] [Abstract][Full Text] [Related]
36. Mortality associated with statins in men with advanced prostate cancer treated with androgen deprivation therapy.
Wu SY; Fang SC; Shih HJ; Wen YC; Shao YJ
Eur J Cancer; 2019 May; 112():109-117. PubMed ID: 30827745
[TBL] [Abstract][Full Text] [Related]
37. Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy.
Grytli HH; Fagerland MW; Fosså SD; Taskén KA; Håheim LL
Prostate; 2013 Feb; 73(3):250-60. PubMed ID: 22821802
[TBL] [Abstract][Full Text] [Related]
38. Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population-based propensity score matching study.
Tae BS; Jeon BJ; Choi H; Bae JH; Park JY
Cancer Med; 2019 Aug; 8(9):4475-4483. PubMed ID: 31183968
[TBL] [Abstract][Full Text] [Related]
39. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
[TBL] [Abstract][Full Text] [Related]
40. Androgen Deprivation Therapy Use in the Setting of High-dose Radiation Therapy and the Risk of Prostate Cancer-Specific Mortality Stratified by the Extent of Competing Mortality.
Rose BS; Chen MH; Wu J; Braccioforte MH; Moran BJ; Doseretz DE; Katin MJ; Ross RH; Salenius SA; D'Amico AV
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(4):778-784. PubMed ID: 27788950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
